Users report steady weight loss, reduced hunger, and better energy levels - the same outcomes most people associate with GLP-1 medication - achieved entirely through the structured eating and movement plan the app provides
In contrast, incretin-based therapies, including GLP-1 receptor agonists (like semaglutide and dulaglutide) and the dual GIP/GLP-1 receptor agonist tirzepatide, do not cause glucosuria and therefore lack this specific mechanism for promoting fungal infections
We offer nutritional counseling, lifestyle modification support, and other integrative therapies to address the root causes of your health issues and enhance the effectiveness of GLP-1 medications
Missed Periods Some women experience skipped or delayed periods after starting tirzepatide, particularly during periods of rapid weight loss
Eating below 1000-1200 calories daily for extended periods increases muscle loss risk and can cause nutrient deficiencies
Archived from the original on October 16, 2017